Leveraging automation: kinetics for derisking chemical processes

  • Reaction
  • 18 November 2025

About

Harnessing reaction kinetics and modelling during process development can help generate process understanding, reduce timelines, control the impurity profile and identify critical process parameters towards robust and optimised processes for scale-up. However, in the absence of automated platforms for parallel kinetics, structured experimentation may be limited by tight timelines and material constraints.

In this webinar, we will aim to demonstrate how leveraging automated technologies for parallel kinetics helps optimise and derisk chemical processes and enable robust scale-up.

Two case studies focused on project delivery, including a transition metal-catalysed reaction and a heterogeneous example, highlight how application of the ReactALL for medium-throughput experimental (MTE) kinetics affords a reduction in both the time required to drive kinetic work packages and in the material required for data generation.

The case studies are based on the work done by the following research team at AstraZeneca, Macclesfield, UK: Hannah Hayes and Ángel Luis Mudarra Alonso with Cristina García Morales, Joel Le Bars, James Barber, Larry Hoteite, Neil Adlington, Mark Dow, and Robert Cox.

Date: Tuesday, 18 November 2025
Time: 4.00 pm CET  |  10:00 am EST  |  7.00 am PST  |  8:30 pm IST
Register here

Guest speaker

Hannah Hayes

Senior Scientist - Mechanistic Chemist at AstraZeneca

Hannah is part of the Chemical Process, Automation & Modelling (CPAM) team in Global Chemical Development, AstraZeneca’s late-stage process chemistry department. She works on projects across the portfolio, both in development and on-market, applying kinetic modelling to support the safe and robust scale-up of chemical processes. Hannah gained her BSc in Chemistry of Pharmaceutical Compounds from University College Cork. Her final year project focused on continuous diazo transfer reactions. During her undergraduate she spent a year studying abroad at the University of California, Irvine, as well as doing a placement in Small Molecule Design and Development at Eli Lilly and Co. in Indianapolis. Hannah obtained a PhD in physical organic chemistry from the University of Edinburgh under the supervision of Prof. Guy Lloyd-Jones FRS. Her research focused on the kinetics and mechanism of the hydrolysis and protodeboronation of (hetero)arylboronic esters. Following her PhD Hannah conducted a postdoc at AstraZeneca working in continuous flow chemistry. In late 2023 Hannah joined AstraZeneca full time as a Senior Scientist.